US2001010815A1PendingUtilityA1
Adeno-associated vector compositions for expression of factor VIII
Priority: Oct 20, 1998Filed: Dec 18, 2000Published: Aug 2, 2001
Est. expiryOct 20, 2018(expired)· nominal 20-yr term from priority
A61K 48/00C12N 2830/008C12N 2799/025C12N 2830/85C07K 14/755A61K 38/37C12N 2830/42C12N 15/86A61P 7/04C12N 2750/14143
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
One form of a composition has two types of recombinant adeno-associated virus. The first type encodes a portion of Factor VIII operably linked to an expression control element; and the second type encodes a different portion of Factor VIII operably linked to an expression control element. The first and second nucleotide sequences collectively encode a functional Factor VIII protein. Another form of the composition is a recombinant adeno-associated virus containing a nucleotide sequence encoding functional Factor VIII light or heavy chain operably linked to a tissue-specific promoter.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A method of treating hemophilia in a human comprsing provding at least one recombinant adeno-associated virion comprising nucleotide sequences encoding Factor VIII and administering said at least one recombinant adeno-associated virion into said human under conditions such that said Factor VIII nucleotide sequences are expressed at a level which provides a therapeutically effective amount in said human.Join the waitlist — get patent alerts
Track US2001010815A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.